Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.

@article{Brunocilla2013SorafenibIH,
  title={Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.},
  author={Paola Rita Brunocilla and Franco Brunello and Patrizia Carucci and Silvia Gaia and Emanuela Rolle and Alessandro Cantamessa and Anna Castiglione and Giovannino Ciccone and Mario Rizzetto},
  journal={Medical oncology},
  year={2013},
  volume={30 1},
  pages={345}
}
Sorafenib is an oral multikinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). In two randomized trials, sorafenib was reported to be safe without a significant impact on quality of life (QoL). The aim of this study was to evaluate the occurrence of adverse events, QoL variations, and treatment discontinuations in HCC patients… CONTINUE READING